Mireille Broeders of the Department for Health Evidence has been appointed full professor of Personalized Cancer Screening. This appointment became effective on 1 May 2020.
Mireille Broeders first got involved with cancer screening during her PhD project (Radboud University, 2004) where she evaluated the impact of the Nijmegen breast screening program, established already in the mid-70s of the last era. Over the past decade, she has developed a research line to identify the added value of introducing personalized risk-based approaches in the current age-based cancer screening programs, with a focus on breast cancer screening. As professor, a key question to address is whether personalized screening strategies, tailored to a person’s individual risk of cancer, are able to improve the balance of benefits and harms related to screening, both for persons at lower and higher than average risk of the cancer. To answer this question, Mireille initiated the nation-wide PRISMA study and created a unique screening cohort where all information to assess a woman’s individual risk for breast cancer has been collected prospectively from 50,000 women. The results of PRISMA will become available over the next five years and are expected to provide the basis for an evidence-based policy decision on personalized breast cancer screening in the Netherlands. Mireille: “But of pivotal importance is that we also understand whether this new personalized risk-based approach is acceptable to citizens and health professionals. Our studies so far strongly indicate that communication will be key in introducing this new approach.” Through her position at the Dutch Expert Centre for Screening (LRCB), Mireille further performs research to improve the quality of breast cancer screening. With her team and collaborators, she explores the possibilities of introducing technological developments, particularly AI algorithms. New potential tests are becoming available rapidly and advances in AI are going particularly fast. However, in cancer screening, where millions of citizens are invited, it is essential to generate high-quality evidence that a “new” test or algorithm is also “better” when it comes to balancing benefits and harms. In the near future, Mireille aims to apply insights gained in breast cancer screening to other established and potential new cancer screening programs, like cervical, esophageal, lung, and prostate cancer.
Mireille is Chair of the International Cancer Screening Network and contributes to the European Commission Initiative on Breast Cancer, as a member of the Guidelines Development Group.
Related news items
650,000 Euro funding for research into the phasing out of medication for leukaemia patients30 July 2020
With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice.read more
Increased role of patients after bowel cancer treatment30 July 2020
Approximately 14,000 patients get colorectal cancer every year. Almost all patients are operated on and monitored afterwards (follow-up). In 2019 Radboudumc started a new approach to follow-up research after the treatment of stage II/III colorectal cancer.read more
Hypatia fellowship Call is open30 July 2020
The Hypatia fellowship round with the deadline 31 May has been canceled. Therefore, the next available deadline will be 27 September 2020. Radboudumc researchers are invited to scout young potentials to fill the strategic gaps within the research themes imbedded in RIHS and RIMLS.read more
Mihai Netea and colleagues published two papers back-to-back in The Journal of Clinical Investigation.29 July 2020
These back-to-back articles investigated the effect of BCG vaccination on trained immunity. The first article shows that BCG vaccination inhibits systemic inflammation, depending on gender. The second article demonstrates that the circadian rhythm influences the induction of trained immunity.read more
Improved method for detecting lung cancer24 July 2020
Radboudumc researchers are the only ones in the Netherlands using a new method to make better lung cancer diagnoses earlier stage. Erik van der Heijden and Roel Verhoeven shows that the use of flexible imaging equipment via the natural respiratory tract contributes to a more accurate diagnosis.read more
Optimizing workup in head and neck cancer (HNC)23 July 2020
In the journal Cancer RIHS researcher Henrieke Schutte described the outcomes after the implementation of a fast-track multidisciplinary integrated HNC care program: time-to-treatment was significantly reduced and survival and patient satisfaction increased significantly without increasing costs.read more